Mylan Lab (NYSE: MYL), a leading pharmaceutical company, closed at $13.53. Goldman Sachs says, "Upgrading to Buy with $19 price target, we see a bottom in shares." MYL overall option implied volatility of 46 is above its 26-week average of 39 according to Track Data, suggesting larger price movement.
Forest Labs (NYSE: FRX), a U.S.-based pharmaceutical company, closed at $36.71. Cowen says "current pipeline is more valuable than generally perceived, and we believe FRX shares can outperform the market by 15-20% as pipeline viability improves." FRX overall option implied volatility of 44 is above its 26-week average of 37 according to Track Data, suggesting larger price movement.
Daily Options Update is provided by Stock Specialist Paul Foster of theflyonthewall.com
Struggling Playboy outsources business ops
J. Crew earnings preview: A strong Q3 all buttoned up?
Twitter to make acquisitions, generate revenue in 2010
